GTC
AXSM icon

Ghost Tree Capital’s Axsome Therapeutics AXSM Stock Holding History

Ghost Tree Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-150,000
Closed -$6.21M – 35
2022
Q1 		$6.21M Buy
+150,000
New +$4.65M 1.35% 16

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ghost Tree Capital's AXSM Position: Q3 2024 in Review

Ghost Tree Capital reduced its Axsome Therapeutics (AXSM) stake by 10% in Q3 2024, selling an estimated $1.31M and leaving 135,000 shares worth $12.1M. The position accounts for 3.66% of the portfolio, ranked #6.

Ghost Tree Capital first reported a position in AXSM in Q1 2019 and has held it in 17 quarters since. The position peaked at $21.9M in Q2 2019. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Ghost Tree Capital held 135,000 shares of Axsome Therapeutics worth $12.1M as of Q3 2024.
  • Ghost Tree Capital sold 15,000 Axsome Therapeutics shares in Q3 2024, an estimated $1.31M.
  • Axsome Therapeutics made up 3.66% of Ghost Tree Capital's portfolio in Q3 2024, its #6 holding.
  • Ghost Tree Capital first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 17 quarters since.
  • Ghost Tree Capital's Axsome Therapeutics position peaked at $21.9M in Q2 2019.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.